What Happened?
Redwood City, CA-based Adverum Appointed Rolf Ramelmeier as Chief Technology Officer
About the Company
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.
About the Person
Rolf Ramelmeier is Chief Technology Officer at Adverum. Previously, Rolf held various senior IT leadership roles in the industry.
Info Source
News
Short Profile